SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), recommended for patients with type 2 diabetes (T2D), heart failure (HF), or chronic kidney disease (CKD), have been shown to reduce serum uric acid (UA) levels through enhanced urinary urate excretion and modulation of metabolic pathways, potentially lowering the risk of incident gout (15–17).